SR-18292 is an inhibitor of PPAR gamma coactivator-1α (PGC-1α), which increases PGC-1α acetylation, suppresses gluconeogenic gene expression and reduces glucose production in hepatocytes.

PGC1α:NA

SR-18292 enhances the association between the transcriptional coactivator PGC-1α and the acetyltransferase GCN5, thereby increasing the acetylation of specific lysine residues on PGC-1α. This modification potentially reduces PGC-1α's gluconeogenic activity by diminishing its ability to co-activate the nuclear hormone receptor HNF4α, subsequently suppressing the gluconeogenic transcriptional function of the HNF4α/PGC-1α complex. This mechanism signifies SR-18292's role in modulating energy homeostasis through the regulation of fat and glucose metabolism by influencing PGC-1α's interaction with key metabolic regulatory proteins.

SR-18292 notably lowers fasting blood glucose levels, enhances hepatic insulin sensitivity, and ameliorates glucose homeostasis in diabetic mice. When administered to mice fed a high-fat diet (HFD)—a model for studying obesity and Type 2 Diabetes (T2D)—through intraperitoneal (I.P.) injection at a dose of 45 mg/kg for three consecutive days, with an additional dose on the fourth day, SR-18292 demonstrates significant reductions in fasting blood glucose levels compared to those in vehicle-treated control mice. Furthermore, SR-18292 treatment notably inhibits the expression of gluconeogenic genes, particularly Pck1, in the livers of these mice, indicating a suppression of a key regulatory pathway responding to fasting.

For determination of GCN5 HAT activity U-2 OS cells overexpressing Ad-GCN5 are treated with SR-18292 (10 μM) for 18 h. Cells are lysed with buffer B (20 mM HEPES-KOH (pH 7.9), 125 mM NaCl, 1 mM EDTA, 1 mM DTT, 1% IGEPAL (v/v), 10% glycerol (v/v), 5 mM NaF, 5 mM β-glycerophosphate, 5 mM sodium butyrate and 10 mM nicotinamide), supplemented with Protease Inhibitor Cocktail. FLAG-GCN5 is immunoprecipitated with FLAG beads overnight at 4°C following multiple washes with lysis buffer. GCN5 is then eluted using 3× FLAG peptide and the purified protein is used to determine HAT activity using the HAT Inhibitor Screening Assay Kit

For cell viability determination using MTT, primary hepatocytes are seeded on a 96-well plate at 20,000 cells/well. The following day cells are treated at different doses, as indicated, for 18 h treatment of primary hepatocytes. 5 μL of MTT reagent (5 mg/mL) is then added to each well (n=4/dose) and cells are incubated for 1h at 37°C. Medium is discarded and dye is extracted by adding 100 μL DMSO to each well. For cytotoxicity determination using ToxiLight Non-destructive Cytotoxicity Bioassay, hepatocytes are seeded on a 6-well plate and treated with either SR-18292 (20 μM) or Cisplatin (50 μM) for 18 h. 50 μL of medium is collected and used to measure cellular toxicity by adding 100 of adenylate kinase detection reagent and incubating 5 min at RT before measuring luminescence[

SR-18292 is re-suspended in a 10% DMSO/10% Tween80/80% PBS solution at a final concentration of 6-12 mg/mL.MiceFor in vivo studies with DIO mice, males 6-8 weeks old are fed high fat diet (HFD) for the indicated time. For drug administration, SR-18292 (45 mg/kg) is injected via I.P. for 3 days between 4-5 pm and food is removed on day 3 at 5pm. The following morning (day 4) SR-18292 is injected again (for a total of 4 injections) and blood glucose is measured after 3 hours. Injection volume does not exceed 275 μL per mouse

Ethanol: 10 mg/mL (27.29 mM), Sonication is recommended.

DMSO: 245 mg/mL (668.49 mM), Sonication is recommended.

H2O: Insoluble

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.46 mM), Sonication is recommended.